IND

RedPlumpTomato

My AI Slop Analysis: **(1/2)** **ADMA -- ADMA Biologics, Inc.** \## One-liner verdict A legitimately profitable plasma drug company doing $530M in annual revenue at 47% operating margins — but the CEO has not bought a single share in the open market in any of his 28 Form 4 filings this past year, just sold $1.76M on the morning after his own earnings beat, and the whole business rides 88% on one product. WATCH. \--- The near-term catalyst calendar is empty. Q3 earnings landed November 4th — $141.1M revenue, 71% gross margin, raised full-year EBITDA guidance to $275M+ — and the market's response was a 3.6% selloff the next day to $12.73. That beat and guidance raise are already priced in. The only pipeline optionality is SG-001, a pneumococcal hyperimmune globulin that hasn't even filed an IND yet — earliest realistic approval is 2030-2031. The market is paying zero for it right now, and it is goddamn right not to. ADMA's story opens in 2006 as "R&R Acquisition VI, Inc." — a blank-check shell, the kind of batshit vehicle name you see more often in enforcement actions than biotech whitepapers. It was reverse-merged and built, painfully slowly, into something real. The company bled through thirteen consecutive loss years, burning roughly $581M in cumulative net losses from FY2011 through FY2023. Then FY2024 happened: $197.7M in net income, first profitable year since FY2011. The stock ran to $20.46 by December 2025, then crater-dived to $7.21 by March 2026. It has since bounced to $12.73 — 76.6% above the low, 37.8% below the peak. The uncomfortable middle. The business is a weird-ass little cash engine by any honest measure. ASCENIV — a hyper-niche immune globulin made from plasma donors selected for high RSV antibody titers, FDA-approved 2019 — posted $124.7M in Q3 revenue, up 31% year-over-year. Total Q3: $141.1M. Gross margin 71%, up 1,450 basis points from a year ago. Nine-month operating margin: 47%. Operating cash flow: $105.2M in nine months versus $14.8M in the same period of 2025. The accumulated deficit has been eaten from -$161.7M at year-end 2025 to -$28.6M as of September 30th — at this pace, the December balance sheet will show positive retained earnings for the first time since FY2011. Nobody is talking about that piece of history. The capital return math sets up a tension worth naming. Through Q3, ADMA spent $181.6M on buybacks in nine months — more than the $133M in net income earned in the same period. Funded through a $300M JPMorgan credit facility drawn to $195.9M. Net debt: $71.3M. Enterprise value: $2.895B. Against $275M EBITDA guidance, that is 10.5x EV/EBITDA. A multiple that says "defensible compounder." The shit that complicates it is in the insider filings. CEO Adam Grossman has zero open-market cash purchases across all 28 Form 4 filings in the past year. His equity relationship is entirely grants, $5.40 option exercises, tax withholdings, and a 10b5-1 sell program entered November 2025 near the stock's high. Prior tranches totaled 84,000 shares sold at $15.16-$19.79. Then November 5th — the morning after Q3 earnings — 147,000 shares at $12.00 flat, $1.764M: seven times the average size of his prior monthly clips. The plan is mechanical. But the man who built this operation through thirteen years of losses, through the $7.21 lows, has not once put his own cash into the stock in any Form 4 filed this past year. That earns the question. Two directors did buy with real cash. Director Jerrold Grossman bought 31,400 shares at $7.99 average in May 2026 — near the low, $250,874, the most honest signal in the whole filing stack. Director Steve Elms bought 14,000 shares at $15.53 average in March for $217,420 — currently underwater at $12.73. Total open-market buying in 365 days: $468,294 from two directors. CEO: zero. The near-the-lows buyer has since stopped. Neither director is buying now. The concentration risk is the whole bet. ASCENIV is 88% of Q3 revenue. The second product, BIVIGAM, did $15.4M in Q3 versus $23.8M a year ago — a 35% year-over-year collapse that looks structural. BIVIGAM is dying while ASCENIV carries the whole goddamn company. ASCENIV is differentiated, the platform is real, and 31% revenue growth is real. But if anything touches it, ADMA has nothing behind it. The retail crowd has not discovered this stock. Ninety days of pulse returns 34 threads with a mean score barely above one, 41% from bot aggregators. No squeeze narrative (9.1% short interest, 3.68 days to cover), no cult. No organic thesis in the top threads — just hold-or-sell chatter. WATCH. The company is real and the business is not bullshit. But 88% single-product, 10.5x EV/EBITDA, CEO running a 10b5-1 that just went 7x in size morning-after a beat, second product in structural decline — that is not the tape that makes you want to get ahead of the market right now. If ASCENIV year-over-year growth holds above 20% in Q4 and the sell program visibly slows, the stock becomes genuinely interesting around current prices. If ASCENIV decelerates below 20%, the entire $530M guide has to be rethought and $12 turns into $8 fast. If the sell program keeps running at the same goddamn size through December, the thesis stays murky until it stops.

AverageNo130

The U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for **DeFloria, Inc.**—a joint venture between Charlotte's Web, Ajna BioSciences, and British American Tobacco—to start a Phase 2 clinical trial for **AJA001 Oral Solution.**

Qweasdy

It’s currently doing exactly that, you just haven’t been paying attention. We’re in the middle of a massive solar power boom. https://ourworldindata.org/grapher/installed-solar-pv-capacity?country=OWID_WRL~CHN~IND~USA~OWID_EUR